University of Bristol 4th May 2011 - PowerPoint PPT Presentation

Loading...

PPT – University of Bristol 4th May 2011 PowerPoint presentation | free to download - id: 5a4a7b-MzFkY



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

University of Bristol 4th May 2011

Description:

University of Bristol 4th May 2011 2.2.2 Human development and ageing HEALTH.2012.2.2.2-1: Integrative systems biology and comparative genomics for studying human ... – PowerPoint PPT presentation

Number of Views:162
Avg rating:3.0/5.0
Slides: 59
Provided by: test48
Category:

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: University of Bristol 4th May 2011


1
University of Bristol 4th May 2011
2
Agenda
  • MRCs role within FP7
  • Funding opportunities within FP7
  • 2012 Health Work Programme
  • Key points
  • Topics by activity area

3
MRC and FP7
  • MRC has four roles in FP7
  • Participant
  • NCP for the Health Theme Victoria Brewer
  • Programme Management Committee (Health) Mark
    Palmer
  • State Representative for Innovative Medicines
    Initiative Jill Jones
  • MRC leads the PMC delegation at the invitation
    of the Department of Business Innovation and
    Skills (BIS)
  • Alternative delegates are
  • Department of Health (DH)
  • Technology Strategy Board
  • Expert group e.g. UKRO
  • Joint lead between MRC and BIS

4
What is FP7
  • Main mechanism used by the European Commission to
    fund research across Europe.
  • Two main aims
  • To strengthen the scientific and technological
    base of European industry.
  • To encourage international competitiveness while
    promoting research that supports EU policies.
  • How does the EC aim to achieve this?
  • Pooling resources
  • Integration of research
  • Excellence in research
  • Addressing Specific Needs
  • Addressing Pan-European challenges
  • Coordinating national and regional programmes
  • Conducting comparative research at EU level
  • Disseminating research result more widely
  • Assembling critical mass
  • Enabling big science
  • Leverage private investment
  • Orphan research
  • Supporting research careers and mobility of
    research
  • Creating world class centres of excellence
  • EU level competition to increase quality and
    creativity

5
FP7 Budget
  • Seven year funding programme with a budget of
    around 50.5 Billion

To date the UK has received 14 of the overall
funding awarded
6
Ideas European Research Council
  • 7.5bn budget
  • Managed through the European Research Council
    (ERC)
  • Bottom up/investigator led research
  • Research within your own team no international
    collaboration
  • ERC Early grants
  • Funding 1.5 M for up to 5 year
  • 2-12 years post PhD at application
  • UK has received 180 grants to date
  • ERC-2010-StG call -79/427 went to UK HEI (19)
  • ERC Advanced Grants
  • Funding 2.5 M for up to 5 year
  • exceptional research leader
  • UK has received 172 grants to date
  • ERC-2010-AdG call - 53/266 went to UK HEI (20)

7
People Marie Curie Actions
  • 4.75bn budget
  • Managed through Marie Curie Actions
  • Research mobility and career development scheme
    inc
  • coordination of PhD programmes
  • Allows for European and International exchange
  • Schemes for individuals or organisations
  • To date 1.3 billion awarded
  • UK share 300.8 million 23
  • Individual
  • Marie Curie Intra-European Fellowships for Career
    Development (IEF) -move from one EU or FP7
    associated country to another for a duration of
    1-2 years.
  • Marie Curie International Incoming Fellowships
    (IIF) bring researchers based outside Europe
    into an EU Member State or country associated to
    FP7 for a duration of 1-2 years.
  • Organisation
  • Initial Training Networks (ITNs) aimed at
    initial training of researchers, first five years
    of researchers' careers. Projects will be based
    around a Joint Training Programme focussing on
    scientific and technological knowledge, as well
    as other complementary skills such as IPR,
    research management, entrepreneurship
  • Co-funding of Regional, National and
    International Programmes (COFUND) - encourage
    existing or new regional or national programmes
    to open up and provide for trans-national
    mobility, as well as to reinforce international
    programmes.

8
Cooperation
  • 32.4bn budget
  • Top-down research
  • EC sets the Research Agenda
  • Proposals must be topic specific
  • Multiple-disciplinary
  • Collaborative research
  • MUST be working with European Partners
  • (or Associated Countries/ target specific
    countries)
  • 3 is a magic number
  • SICA 2x MS/AC 2x target region(s)

9
Who is eligible to participate?
  • EU-27 Member States (MS)
  • Austria, Belgium, Bulgaria , Cyprus, Czech
    Republic, Denmark, Estonia, Finland, France,
    Germany, Greece, Hungary, Italy, Ireland, Latvia,
    Lithuania, Luxemburg, Malta, Netherlands, Poland,
    Portugal, Romania, Slovakia, Slovenia, Spain,
    Sweden, UK
  • Associated Countries (AC)
  • Albania, Bosnia and Herzegovina , Croatia,
    Faroe Islands, FYR, Macedonia, Iceland,
    Israel, Liechtenstein, Montenegro, Norway,
    Serbia, Switzerland, Turkey
  • except Euratom

10
Third countries ICPC
11
What organisation can participate?
  • Participation is open to a wide range of
    organisations and individuals
  • research groups at universities or research
    institutes
  • small or medium-sized enterprises (SMEs)
  • SME associations or groupings
  • public or governmental administration (local,
    regional or national)
  • organisations and researchers from third
    countries
  • international organisations
  • civil society organisations
  • Need to register your organisation with the EC

12
Cooperation
Health 6.1bn
Food, Agriculture, Fisheries, Biotechnology 1.9bn
Information and Communication Technologies 9.1bn
Nano-sciences, nano-technologies, materials and new production technologies 3.5bn
Energy 2.4bn
Environment 1.9bn
Transport 4.2bn
Socio-economic sciences and the humanities 0.6bn
Space 1.4bn
Security 1.4bn
Obesity, allergies, zoonoses and systems biology
Medication information technologies, activities
on ageing, patient safety and virtual
physiological human being
Biomaterials for health application,
nanomedicines and nanotoxicology
Environment and Health
13
2012 Health Work Programme
  • Research priorities
  • Active Healthy Ageing
  • Europe 2020 - Innovation Union ? The pilot
    European Innovation Partnership on active and
    healthy ageing
  • 5 topics each looking to fund more than 1
    proposal, 4x 6m and 1x 12m
  • Medical technologies
  • Supporting the innovation" strategy and reduce
    the time to market
  • 7 topics each looking to fund more than 1
    proposal, 6x 6m and 1x 3m
  • Rare diseases
  • Build critical mass for research on rare diseases
  • Currently 4 topics and 1 HIP but likely to become
    7 topics
  • Clinical Trials
  • Continue on initiative started in 2011 work
    programme
  • Improve the quality of clinical trial data in
    Europe
  • 1x Active and Healthy ageing, 2x Rare diseases
    and 1xDiabetes (type 1)

14
2012 Health Work Programme
  • Key features to look out for..
  • Strong SME focus in the majority of call topics
  • SME-targeted ? 30 budget
  • SME-focus ? 15 budget
  • Majority of call are 2 stage (exceptions CSA and
    ERA Net)
  • Process
  • Outline submission
  • Invitation to second stage
  • Full proposal submission
  • Results

2011 WP Deadline 13th Oct 2010 20th Dec
2010 10th Feb 2011 end April/early May 2011
15
2012 Health Work Programme
  • CLOSED AREAS
  • BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL
    TECHNOLOGIES FOR HUMAN HEALTH
  • 1.1 High-throughput research
  • 1.3 Suitability, safety, efficacy of therapies
  • 2. TRANSLATING RESEARCH FOR HUMAN HEALTH
  • 2.2.1 Brain and brain-related diseases
  • 2.3.1 Anti-microbial drug resistance
  • 2.3.3 Potentially new and re-emerging epidemics
  • 2.3.4 Neglected infectious diseases
  • 2.4.1 Cancer
  • 2.4.2 Cardiovascular diseases
  • 3. OPTIMISING THE DELIVERY OF HEALTHCARE TO
    EUROPEAN CITIZENS
  • 3.1 Translating the results of clinical research
    outcome into clinical practice including better
    use of medicines, and appropriate use of
    behavioural and organisational interventions and
    new health therapies and technologies
  • 3.3 Health promotion and prevention
  • 4. OTHER ACTIONS ACROSS THE HEALTHTHEME

16
The Health Theme
1 Biotechnology, generic tools and medical
technologies for human health
2 Translating research for human health
3 Optimising the delivery of healthcare to
European citizens
4 Emerging policy needs/unforeseen needs
17
1.2 DETECTION, DIAGNOSIS AND MONITORING
  • HEALTH.2012.1.2-1. Development of technologies
    with a view to patient group stratification for
    personalised medicine applications.
  • Key points
  • SME-targeted Collaborative Project up to 6m
  • One or more proposals can be selected.
  • Two-stage call
  • Focus
  • Research and development of technologies ?
    application of tailored medical intervention in
    specifically defined patient group
  • Proof of principle highlighted
  • Emphasis of data collection and analysis i.e.
    statistical tool quality control around this
  • Active inclusion of end users (particular for
    proof of principle)

18
1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES
  • Innovative Medicines Initiative
  • Joint EC and EFPIA funding scheme 2 billion
  • Research areas in
  • Safety
  • Efficacy
  • Education training
  • Knowledge management
  • 4th call Estimated launched in June 2011
  • Indicative topics
  • Assessment of drug-induced toxicity in relevant
    organs surrogates for early drug failure
  • Enhancing translation in neurological diseases
  • European Medical Information Systems
  • Stem Cells for drug development and toxicity
    screening
  • Beyond high-throughput screening
  • Disease heterogeneity/taxonomy of disease
  • Genetic mapping of extreme phenotypes
  • Combination therapy development

19
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND
INTERVENTIONS
  • Focus Transplantation
  • Rationale
  • Clinical demand
  • Continuity of successful FP6 projects
  • Recent progress in other areas
  • Policy developments i.e. DG SANCO

20
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND
INTERVENTIONS
  • HEALTH.2012.1.4-1 Innovative approaches to solid
    organ transplantation.
  • Key points
  • SME-focused Collaborative Project up to 6m
  • One or more proposals can be selected.
  • Two-stage call
  • Focus
  • Improve the outcome, increase efficiency /or
    widen the scope of solid transplantation
  • Clinical focus inc. Regulatory, safety
    immunological aspects
  • Improved treatment ? improved personal targeting
    tolerance

21
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND
INTERVENTIONS
  • HEALTH.2012.1.4-2 Medical technology for the
    transplantation sector and bioartificial organs
  • Key points
  • SME-targeted Collaborative Project up to 6m
  • One or more proposals can be selected.
  • Two-stage call
  • Focus
  • Develop novel tools, techniques devices for use
    in transplantation and in bioartifical organs
  • Include cells, tissues or organs
  • Clinical/in-patient trial central to the
    proposal
  • Cover safety efficacy assessment regulatory
    work

22
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND
INTERVENTIONS
  • HEALTH.2012.1.4-3 Innovative strategies for
    translation of stem cell based therapies in
    regenerative medicine.
  • Key points
  • SME-targeted Collaborative Project up to 6m
  • One or more proposals can be selected.
  • Two-stage call
  • EU and Australia Cooperation
  • Australian Partners 50 work carried out in
    Australia
  • Joint submission to EC and NHMRC
  • Australian Partners apply to NHMRC ? request EU
    funds ? 6m max EC contribution to European Team
  • Max NHMRC contribution 6m

23
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND
INTERVENTIONS
  • HEALTH.2012.1.4-2 cont.
  • Focus
  • Characterisation
  • Mechanisms of action and nature of host
    response(s)
  • Quality control of product(s),
  • Efficacy and safety in relevant preclinical
    models
  • Bridging studies can be included
  • 2 phase project ? 2nd stage dependent on
    regulatory approval
  • 5 year review at Yr 3 ? Yrs 45 dependent on
    approval of joint regulatory filing
  • funds divided equally between the 2 phases
  • Outcome Therapeutic products clinical
    protocols developed with industrial partners

24
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND
INTERVENTIONS
  • HEALTH.2012.1.4-4 Targeted nucleic acid delivery
    as an innovative therapeutic or prophylactic
    approach.
  • Key points
  • SME-targeted Collaborative Project up to 6m
  • One or more proposals can be selected.
  • Two-stage call
  • Focus
  • Immunotherapy, gene therapy or DNA vaccination,
    RNA interference
  • Clinical testing carried out throughout of the
    life time of the project inc. regulatory work
  • Preclinical work around safety, immunogenicity,
    toxicity and feasibility studies should have
    already been completed

25
The Health Theme
1 Biotechnology, generic tools and medical
technologies for human health
2 Translating research for human health
3 Optimising the delivery of healthcare to
European citizens
4 Emerging policy needs/unforeseen needs
26
2.1 INTEGRATING BIOLOGICAL DATA AND PROCESSES
LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY
  • 2.1.1 Large-scale data gathering
  • HEALTH.2012.2.1.1-1 Clinical utility of -omics
    for better diagnosis and treatment of rare
    diseases.
  • Key points
  • WAS a High Impact Project going to broken down
    into individual Collaborative Project
  • Focus
  • New topics Still TBC
  • Likely to cover
  • -omics approaches and technologies for molecular
    characterisation for a chosen rare disease ? new
    diagnostics and treatment in clinical settings
  • Utilisation of existing databases/biobanks
  • Coordination and harmonisation of patient
    registries

27
2.1.1 Large-scale data gathering (cont.)
  • HEALTH.2012.2.1.1-2 Validation of -omics-based
    biomarkers for diseases affecting the elderly.
  • Key points
  • SME-targeted Collaborative Project up to 12m
  • One or more proposals can be selected.
  • Two-stage call
  • Focus
  • Clinical validation already identified -omics
    based biomarkers ? sensitivity, specificity and
    predictive power ? improved diagnosis, prognosis,
    patient stratification and/or treatment
    monitoring
  • Inc. statistical models and quality control for
    data generated

28
2.1.1 Large-scale data gathering (cont.)
  • HEALTH.2012.2.1.1-3 Statistical methods for
    collection and analysis of -omics data.
  • Key points
  • SME-targeted Collaborative Project up to 6m
  • One or more proposals can be selected.
  • Two-stage call
  • Focus
  • Improve or develop new statistical models / tools
    for analysis of omic based data
  • Open to any omics based data e.g. genomics,
    proteomics etc or particular class of analysis
  • Clinical trials excluded
  • Must include appropriate training and
    dissemination activities

29
2.1 INTEGRATING BIOLOGICAL DATA AND PROCESSES
LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY
  • 2.1.2 Systems biology
  • HEALTH.2012.2.1.2-1 Systems medicine SME-driven
    research applying systems biology approaches to
    address medical and clinical needs.
  • Key points
  • SME-targeted Collaborative Project up to 3m
  • One or more proposals can be selected.
  • Two-stage call
  • Small to minimum consortium sizes
  • Project duration up to 2 years
  • No intermediate payments or reports

30
2.1.2 Systems biology (cont.)
  • HEALTH.2012.2.1.2-1 cont.
  • Focus
  • Development, improvement and application of
    systems biology approaches to medical/clinical
    questions e.g.
  • Re-design of clinical trials by shortening
    timescale and costs
  • Development of combinatorial therapies and/or
    chronotherapies for complex diseases
  • Development of combinatorial biomarkers
  • Etc
  • Establish proof-of-concept ? demonstrate the
    potential for exploitation
  • Exploitation of results in clinical an/ or
    industrial sectors

31
2.1.2 Systems biology (cont.)
  • HEALTH.2012.2.1.2-2 Systems medicine Applying
    systems biology approaches for understanding
    complex human diseases and their co-morbidities.
  • Key points
  • Collaborative Project up to 12m
  • One or more proposals can be selected.
  • Two-stage call
  • Focus
  • Integrated multidisciplinary research inc.
    pre-clinical and clinical research ? clinicians,
    biologists computational scientists,
    mathematician etc
  • Address a clear clinical need ? new avenues of
    understanding patho-physiology, diagnosis and
    treatment of complex diseases

32
2.1.2 Systems biology (cont.)
  • HEALTH.2012.2.1.2-3 Preparing for the future
    research and innovation activities in systems
    medicine.
  • Key points
  • Coordination and Support Action (CAS) up to 3m
  • Only one proposals can be selected.
  • Two-stage call
  • Focus
  • Promote, support and coordinate research
    activities in systems biology across Europe
  • Best practice, information and resources of
    successful methodological approaches.
  • Multidisciplinary training requirements for the
    next generation
  • Promote innovation activities ? technology
    transfer exploitation

33
2.2 RESEARCH ON THE BRAIN AND RELATED DISEASES,
HUMAN DEVELOPMENT AND AGEING
  • 2.2.2 Human development and ageing Primary
    focus
  • Rationale
  • Europe has highest proportion of older people in
    the world
  • Grand challenge of understanding the ageing
    process
  • More targeted geriatric medicines
  • Innovation Union partnership Active and Healthy
    Ageing
  • http//ec.europa.eu/research/innovation-union/inde
    x_en.cfm?sectionactive-healthy-ageing

34
2.2.2 Human development and ageing
  • HEALTH.2012.2.2.2-1 Integrative systems biology
    and comparative genomics for studying human
    ageing and/or most common age-related diseases.
  • Key points
  • SME-targeted Collaborative Project up to 6m
  • One or more proposals can be selected.
  • Two-stage call
  • Focus
  • Interactions between genetics, epigenetic and
    environmental factors ? ageing phenotype in
    normal and disease conditions
  • Computational approaches, comparative genomic
    studies of existing data and appropriate
    modelling
  • Can include tools for diagnosis, prognosis and
    monitoring of therapies

35
2.2.2 Human development and ageing (cont.)
  • HEALTH.2012.2.2.2.-2 Investigator-driven
    clinical trials for optimisation of management of
    elderly patients with multiple diseases.
  • Key points
  • SME-targeted Collaborative Project up to 6m
  • One or more proposals can be selected.
  • Two-stage call
  • Focus
  • Compare various treatment regimens in elderly
    population treated for multiple diseases
  • Clinical trials looking at efficacy and adverse
    effects of multi treatment of common age related
    diseases

36
2.3 TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS
DISEASES TO CONFRONT MAJOR THREATS TO PUBLIC
HEALTH
  • 2.3.0 Cross-cutting
  • HEALTH.2012.2.3.0-1 Diagnostics for infectious
    diseases.
  • Key points
  • SME-targeted Collaborative Project up to 6m
  • One or more proposals can be selected.
  • Two-stage call
  • No prescribed duration i.e. can be as short as
    1-2 years
  • Focus
  • Development and/or validation of diagnostic tests
    for major infectious diseases to meet clinical
    need
  • Priority to diseases with unmet medical need
    i.e. no tests available improved testing ?
    better control and management

37
2.3 TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS
DISEASES TO CONFRONT MAJOR THREATS TO PUBLIC
HEALTH
  • 2.3.2 HIV/AIDS, malaria and tuberculosis
  • HEALTH.2012.2.3.2-1 Co-infection of HIV/AIDS,
    malaria, tuberculosis and/or hepatitis.
  • Key points
  • Collaborative Project up to 6m
  • One or more proposals can be selected.
  • Two-stage call
  • Focus
  • Basic, translation and/or clinical research
  • prevention, therapeutic management and prognosis
    of co-infected patients
  • Immunological mechanisms and response to
    co-infection
  • Priority to co-morbidity of relevance to LMIC

38
2.3.2 HIV/AIDS, malaria and tuberculosis (cont.)
  • HEALTH.2012.2.3.2-2 Co-morbidity between
    infectious and non-communicable diseases.
  • Key points
  • Collaborative Project up to 6m
  • One or more proposals can be selected.
  • Two-stage call
  • Focus
  • Basic, translation and/or clinical research
  • prevention, therapeutic management and prognosis
    of patients infectious and non-communicable
    diseases
  • Proposals should address
  • Causative links between infectious and
    non-infectious diseases
  • Combination of 3 major poverty related diseases
    (AIDS, malaria or TB) or any major poverty
    related diseases with non-infectious diseases

39
2.3.2 HIV/AIDS, malaria and tuberculosis (cont.)
  • HEALTH.2012.2.3.2-3 Prevention and treatment for
    HIV/AIDS, malaria and tuberculosis.
  • Key points
  • SME-targeted collaborative Project up to 6m
  • One or more proposals can be selected.
  • Two-stage call
  • No prescribed duration i.e. can be as short as
    1-2 years
  • Focus
  • Basic or translation research addressing current
    gaps in
  • Prevention and/or treatment of poverty related
    diseases (HIV/AIDS, malaria or TB)
  • Proposal must inc
  • Detailed plan for exploitation of end results
  • Explore synergies with relevant EU funded
    initiatives e.g. European and Developing
    Countries Clinical Trial Partnership (EDCTP)

40
2.3.2 HIV/AIDS, malaria and tuberculosis (cont.)
  • HEALTH.2012.2.3.2-4 Low-cost interventions for
    disease control in resource poor settings.
  • Key points
  • Collaborative Project up to 3m
  • One or more proposals can be selected.
  • Two-stage call
  • Focus
  • Innovative ways to control neglected infectious
    diseases and/or malaria ? low-cost interventions
    immediate impact
  • Novel applications of current tools and knowledge
    ? new cost-effective solutions
  • Combinational therapy, treatment strategies,
    epidemiology, access to diagnostics and drugs,
    operational and implementation research
  • Inclusion of partners from disease-endemic
    countries

41
2.4 TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES
  • 2.4.3 Diabetes and obesity
  • HEALTH.2012.2.4.3-1 Innovative approach to
    manage diabetes.
  • Key points
  • SME-targeted Collaborative Project up to 6m
  • One or more proposals can be selected.
  • Two-stage call
  • Focus
  • Management of diabetes in pre-and/or clinical
    settings by validating therapeutic devices or
    biological therapies
  • Attention to safety, bio-compatibility,
    interoperability and regulatory aspects ? fast
    and safe uptake of approaches/technologies

42
2.4.3 Diabetes and obesity (cont.)
  • HEALTH.2012.2.4.3-2 Investigator-driven clinical
    trials for type 1 diabetes research.
  • Key points
  • Collaborative Project up to 6m
  • One or more proposals can be selected.
  • Two-stage call
  • Focus
  • Clinical Trial on type 1 diabetes with focus on
    paediatric population ? improve glycolic control
    and/or reduce diabetes complications
  • Inform clinical management of type 1 diabetes
  • Excludes pilot studies and systematic reviews

43
2.4 TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES
  • 2.4.4 Rare diseases ( lt 5/10,000)
  • HEALTH.2012.2.4.4-1 Preclinical and/or clinical
    development of substances with a clear potential
    as orphan drugs.
  • Key points
  • Collaborative Project up to 6m
  • One or more proposals can be selected.
  • Two-stage call
  • Focus
  • MUST be EU designated orphan medicinal products
  • http//ec.europa.eu/health/documents/community-reg
    ister/html/orphreg.htm
  • Preclinical studies in models and/or clinical
    studies
  • Excludes cancer and diseases of the nervous
    system

44
2.4.4 Rare diseases (cont.)
  • HEALTH.2012.2.4.4-2 Observational trials in rare
    diseases.
  • Key points
  • Collaborative Project up to 3m
  • One or more proposals can be selected.
  • Two-stage call
  • Focus
  • Rare diseases with no orphan drug available
    treated off-label
  • Improve clinical management of rare diseases ?
    evidence based clinical guidance
  • Data collection and comparing outcomes of various
    treatment regimens
  • Evaluation of effectiveness and adverse events
  • Excludes cancer, infectious diseases and diseases
    of the nervous system

45
2.4.4 Rare diseases (cont.)
  • HEALTH.2012.2.4.4-3 Best practice and knowledge
    sharing in the clinical management of rare
    diseases.
  • Key points
  • Coordination and Support Action (CAS) up to 2m
  • Only one proposals can be selected.
  • Two-stage call
  • Focus
  • Development of a networking platform supporting
    the collection of standardised validated data
    and exchange of information providing evidence of
    best clinical management of rare diseases
  • Identify additional research needs
  • Any group of rare diseases

46
2.4 TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES
  • 2.4.5 Other chronic diseases
  • HEALTH.2012.2.4.5-1 Technological approaches to
    combating sensory impairments.
  • Key points
  • SME-targeted Collaborative Project up to 6m
  • One or more proposals can be selected.
  • Two-stage call
  • Focus
  • Preclinical and clinical testing of novel tools,
    devices or therapies' for overcoming sensory
    disability
  • Prevention and treatment strategies,
    technological approaches, biological cell based
    therapies inc. Stem cells and development of
    bio-artificial organs

47
2.4.5 Other chronic diseases (cont.)
  • HEALTH.2012.2.4.5-2 Biomarkers and diagnostics
    for chronic inflammatory diseases of the joints
    and/or digestive system.
  • Key points
  • SME-targeted Collaborative Project up to 6m
  • One or more proposals can be selected.
  • Two-stage call
  • Focus
  • Development of improved/novel methodologies ?
    early diagnosis of chronic inflammatory diseases
  • Indicative markers for inflammatory onset and
    development evaluation of intervention therapies

48
The Health Theme
1 Biotechnology, generic tools and medical
technologies for human health
2 Translating research for human health
3 Optimising the delivery of healthcare to
European citizens
4 Emerging policy needs/unforeseen needs
49
3.2 QUALITY, EFFICIENCY AND SOLIDARITY OF
HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH
SYSTEMS
  • HEALTH.2012.3.2-1 Improving the organisation of
    health service delivery.
  • Key points
  • Collaborative Project up to 3m
  • One or more proposals can be selected.
  • Two-stage call
  • 4 year duration
  • Focus
  • Best practice for European health care
    organisations around, structure, care processes
    and performance
  • Areas to be addressed (either one or many)
  • integration of patient care
  • Patient centred care and involvement
  • Skill mix and management of resources (only 1
    proposal)
  • Transfer of knowledge into practice span 5
    years

50
3.2 QUALITY, EFFICIENCY AND SOLIDARITY OF
HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH
SYSTEMS
  • HEALTH.2012.3.2-2 New methodologies for health
    technology assessment.
  • Key points
  • Collaborative Project up to 3m
  • One or more proposals can be selected.
  • Two-stage call
  • Focus
  • Develop new and/or improved methodologies for
    Health Technology Assessment (HTA)
  • Areas of focus (either or both)
  • Methodologies for addressing the complexity of
    interventions
  • Methodologies to assess the efficacy and
    effectiveness of technologies
  • Complement previously funded work i.e. EUnetHTA
    JA

51
3.4 INTERNATIONAL PUBLIC HEALTH HEALTH SYSTEMS
  • HEALTH.2012.3.4-1 Health systems/services
    research in low and middle income countries.
  • Key points
  • SICA up to 6m
  • 6x ICPC and min 2x EU/AC
  • One or more proposals can be selected.
  • Two-stage call
  • 5 years in duration
  • Focus
  • Collection, analysis and translation of data into
    effective health service planning and policy
  • Focus on (either)
  • Methods to investigate country comparisons and
    scientific capacity
  • Human resources for health
  • Knowledge transfer
  • Balanced partnership

52
The Health Theme
1 Biotechnology, generic tools and medical
technologies for human health
2 Translating research for human health
3 Optimising the delivery of healthcare to
European citizens
4 Emerging policy needs/unforeseen needs
53
4.1 COORDINATION AND SUPPORT ACTIONS ACROSS THE
THEME
  • HEALTH.2012.4.1-1 Network to encourage knowledge
    transfer activity in FP-funded health research
    (especially in academic and governmental
    organisations). CSA 2m
  • HEALTH.2012.4.1-2 Training actions linked to
    intellectual property rights management and
    knowledge transfer. CSA 2m
  • HEALTH.2012.4.1-3 Support for Presidency events
    Organisation of supporting actions and events
    related to the Presidency of the European Union.
    CSA 100,000
  • HEALTH.2012.4.1-4 Support for the international
    rare disease research. CSA 100,000
  • HEALTH.2012.4.1-5 Communicating the benefits of
    European research to the general public. CSA
    100,000

54
(No Transcript)
55
Contacts
  • NCP Health (Academia) Victoria Brewer
    victoria.brewer_at_headoffice.mrc.ac.uk
  • 020 7395 2205
  • NCP Health (Industry) Graham Hughes
  • graham.hughes_at_betatechnology.co.uk
  • 01302 322633
  • NCP ERC Marie Curie UK Research Office
    ukro_at_bbsrc.ac.uk
  • 00 32 2 230 1535 /5275

56
Useful websites
  • EC website
  • http//cordis.europa.eu/fp7/home_en.html
  • Connect FP7
  • https//ktn.innovateuk.org/web/fp7uk
  • UKRO website
  • http//www.ukro.ac.uk/
  • MRC website International funding opportunties
  • http//www.mrc.ac.uk/Fundingopportunities/Interna
    tionalopportunities/index.htm

57
Useful websites
  • Europe 2020 Strategy
  • http//ec.europa.eu/resource-efficient-europe/
  • Innovation Union http//ec.europa.eu/research/inno
    vation-union/index_en.cfm?pgintro
  • Active and Healthy Ageing http//ec.europa.eu/rese
    arch/innovation-union/index_en.cfm?sectionactive-
    healthy-ageing
  • EDCTP
  • http//www.edctp.org/

58
Any questions?
About PowerShow.com